

**Amendments to the Specification:**

Please amend the specification as follows.

Please substitute the following paragraph for the one bridging pages 10-11.

--Reshaped human antibodies may also be used according to the invention. These are prepared by using the complementary determinant region of a mouse or other non-human mammalian animal antibody to replace the complementary determinant region of a human antibody, and conventional gene recombination methods therefore are well-known. One of the known methods may be used to obtain a reshaped human antibody which is useful according to the invention. A preferred example of such a reshaped human antibody is hPM-1 (see Intl. Unexamined Patent Application No. WO92-19759), which includes a humanized PM-1 antibody that comprises:

(A) L chains of an antibody to the human IL-6 receptor, each comprising:

(1) a variable (V) region of a light (L) chain of an antibody to the human IL-6 receptor having the following structure:

FR1<sup>1</sup>-CDR1<sup>1</sup>-FR2<sup>1</sup>-CDR2<sup>1</sup>-FR3<sup>1</sup>-CDR3<sup>1</sup>-FR4<sup>1</sup>

wherein CDR1<sup>1</sup>, CDR2<sup>1</sup> and CDR3<sup>1</sup> represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:

CDR1<sup>1</sup> Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn (SEQ ID NO: 2)

CDR2<sup>1</sup> Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 3)

CDR3<sup>1</sup> Gln Gln Gly Asn Thr Leu Pro Tyr Thr (SEQ ID NO: 4);  
and the FR1<sup>1</sup>, FR2<sup>1</sup>, FR3<sup>1</sup> and FR4<sup>1</sup> comprise a set of

the following amino acid sequences:

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO: 5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu  
Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr  
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp  
Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 7)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys; (SEQ ID NO: 8)

or

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO: 5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 9)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 8);

and

(2) a C region of an L chain of a human antibody C $\kappa$ ; and [[N]]

(B) H chains of an antibody to the human IL-6 receptor, each comprising:

(1) a V region of a heavy (H) chain of an antibody to the human IL-6 receptor having the following structure:

FR1<sup>2</sup>-CDR1<sup>2</sup>-FR2<sup>2</sup>-CDR2<sup>2</sup>-FR3<sup>2</sup>-CDR3<sup>2</sup>-FR4<sup>2</sup>

wherein CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:

CDR1<sup>2</sup> Ser Asp His Ala Trp Ser (SEQ ID NO: 10)

CDR2<sup>2</sup> Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser Leu Lys Ser (SEQ ID NO: 11)

CDR3<sup>2</sup> Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr (SEQ ID NO: 12);

and the FR1<sup>2</sup>, FR2<sup>2</sup>, FR3<sup>2</sup> and FR4<sup>2</sup> comprise a set of the following amino acid sequences:

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr (SEQ ID NO: 13)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met  
Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met  
Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

or

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 20)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16); and

(2) a C region of an H chain of a human antibody C $\gamma$ ).--